Welcome to our dedicated page for JNCE news (Ticker: JNCE), a resource for investors and traders seeking the latest updates and insights on JNCE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JNCE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JNCE's position in the market.
Jounce Therapeutics (NASDAQ: JNCE) reported its Q3 2022 financial results, ending the quarter with $130.3 million in cash. The company is actively advancing its clinical pipeline, presenting Phase 1 and Phase 2 trial data for JTX-8064 and pimivalimab at the upcoming ESMO-IO Congress. Key highlights include completed enrollment in initial cohorts of the INNATE Phase 2 trial and promising early efficacy signals. Despite a $31 million net loss for the quarter, management projects sufficient cash to fund operations into Q1 2024 and reaffirms their 2022 financial guidance.
Jounce Therapeutics (NASDAQ: JNCE) announced a $15 million milestone payment from Gilead Sciences (NASDAQ: GILD) linked to the exclusive licensing agreement for GS-1811, an anti-CCR8 antibody aimed at cancer treatment. This payment is part of a broader deal signed in September 2020, where Gilead invested $35 million in Jounce's common stock and paid $85 million upfront. Jounce could earn up to $645 million in future milestones and is entitled to royalties based on worldwide sales.
Jounce Therapeutics, Inc. (NASDAQ: JNCE) has announced it will report its third quarter 2022 financial results and provide a corporate update on November 10, 2022. The event will feature a live conference call and webcast at 8:00 a.m. ET. Jounce is focused on developing cancer immunotherapies and predictive biomarkers, with ongoing development programs including its leading candidates JTX-8064 and vopratelimab. These therapies aim to enhance the immune system's ability to fight tumors, showcasing Jounce’s commitment to innovative cancer treatment.
Jounce Therapeutics announced two preclinical and two clinical poster presentations at major medical meetings. The preclinical posters focus on the JTX-1484 program targeting LILRB4 and its role in immune cell function in tumors. These will be presented at the SITC 2022 meeting from November 8-12 in Boston. At the ESMO-IO 2022 Congress in Geneva, December 7-9, Jounce will present Phase 1 data on the JTX-8064 INNATE trial and additional durability data from the SELECT trial. The company expects to report preliminary data on 80 Phase 2 patients by the end of 2022.
On September 7, 2022, Jounce Therapeutics (NASDAQ: JNCE) announced participation in two investor conferences in New York this September. The company will engage in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 10:00 a.m. ET and participate in a panel at the Cantor Oncology Conference on September 28 at 2:35 p.m. ET. Interested parties can access the webcasts via Jounce’s website, with replays available for 30 days.
Jounce focuses on cancer immunotherapy and has several promising therapeutic candidates in development.
Jounce Therapeutics announced that the SELECT trial for vopratelimab in combination with pimivalimab did not meet the primary endpoint of mean tumor change averaged over 9 and 18 weeks. Although the combination showed encouraging trends, particularly with a 40% overall response rate compared to 25% for pimivalimab alone, the trial's actual difference was only 7%, against a goal of 20%. Vopratelimab demonstrated tolerability, and pimivalimab's safety profile remained strong. Next steps include a clinical abstract submission for the ESMO Immuno-Oncology Congress in December 2022.
Jounce Therapeutics reported its Q2 2022 financial results, showing a net loss of $33.5 million, up from $4 million in Q2 2021. The cash position decreased to $162.3 million, down from $220.2 million at year-end 2021. The company completed patient enrollment in its Phase 2 SELECT trial and is set to present preliminary data for the INNATE trial by year-end 2022. Despite increased operating expenses, Jounce remains optimistic, expecting sufficient cash to fund operations into Q1 2024. The company continues advancing its immunotherapy pipeline and submitted abstracts for upcoming conferences.
Jounce Therapeutics (NASDAQ: JNCE) will report its second quarter 2022 financial results and provide a corporate update on August 4, 2022. A webcast and conference call will be held at 8:00 a.m. ET. Jounce is focused on developing cancer immunotherapies and predictive biomarkers. The company is advancing multiple clinical programs, including JTX-8064, a receptor antagonist, currently in Phase 1/2 trials, and vopratelimab, studied in the SELECT Phase 2 trial. Investors can access the call via registration or through the company's website.
Jounce Therapeutics (NASDAQ: JNCE) will participate in two upcoming investor conferences. The H.C. Wainwright Global Investment Conference will feature an on-demand presentation available starting May 24, 2022, at 7:00 a.m. ET. The Cowen’s 3rd Annual Oncology Innovation Summit will include a live presentation on June 2, 2022, at 1:30 p.m. ET. Webcasts of both events can be accessed on Jounce's website, with replays available for 30 days post-event. Jounce focuses on developing cancer immunotherapies and is advancing multiple clinical programs.
Jounce Therapeutics (NASDAQ: JNCE) reported Q1 2022 results, ending with $186.4 million in cash. Two INNATE trial cohorts met response criteria for expansion, with preliminary data expected in 2H 2022. In the SELECT trial, target enrollment was achieved, and the company plans to present data later this year. R&D expenses rose to $30.1 million, with a net loss of $37.4 million, translating to a net loss per share of $0.72. Jounce reaffirms its guidance, expecting a gross cash burn of $115 million to $130 million for 2022.
